Keros Therapeutics Announces First Patient Dosed In Phase 3 RENEW Clinical Trial Of Elritercept In Adults With Transfusion-Dependent Anemia With Very Low, Low, Or Intermediate Risk MDS

Author: Benzinga Newsdesk | July 17, 2025 08:16am

Keros Therapeutics, Inc. ("Keros") (NASDAQ:KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta ("TGF-ß") family of proteins, today announced that the first patient was dosed in the Phase 3 RENEW clinical trial of elritercept in adults with transfusion-dependent anemia with very low, low, or intermediate risk myelodysplastic syndromes ("MDS"). The dosing of the first patient triggers a $10 million milestone payment to Keros under the global license agreement with Takeda.

Posted In: KROS